QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
QQQ   444.47 (-0.08%)
AAPL   170.92 (-1.38%)
MSFT   420.85 (-0.14%)
META   488.12 (-1.16%)
GOOGL   150.51 (-0.24%)
AMZN   180.76 (+0.52%)
TSLA   176.29 (-1.97%)
NVDA   905.25 (+0.30%)
NIO   4.61 (-1.28%)
AMD   181.46 (+1.04%)
BABA   72.51 (+1.29%)
T   17.57 (+0.11%)
F   13.28 (+1.68%)
MU   118.47 (-0.56%)
CGC   9.45 (-1.05%)
GE   175.44 (-2.60%)
DIS   122.70 (+1.42%)
AMC   3.69 (-14.98%)
PFE   27.88 (+0.36%)
PYPL   66.82 (+0.38%)
XOM   115.52 (+0.48%)
NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

$1.63
+0.04 (+2.52%)
(As of 11:43 AM ET)
Today's Range
$1.57
$1.67
50-Day Range
$1.24
$1.99
52-Week Range
$0.62
$2.50
Volume
81,594 shs
Average Volume
610,722 shs
Market Capitalization
$21.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Iterum Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
261.4% Upside
$6.00 Price Target
Short Interest
Bearish
9.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Iterum Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.04) to ($3.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.37 out of 5 stars

Medical Sector

752nd out of 939 stocks

Biotechnology Industry

11th out of 20 stocks

ITRM stock logo

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Stock Price History

ITRM Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Iterum Therapeutics (ITRM) Set to Announce Earnings on Thursday
Iterum Therapeutics Provides Business Update
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Iterum Therapeutics PLC (ITRM)
Q3 2023 Iterum Therapeutics PLC Earnings Call
Iterum Therapeutics GAAP EPS of -$0.30
Recap: Iterum Therapeutics Q3 Earnings
See More Headlines
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ITRM
Fax
N/A
Employees
14
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+277.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-44,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.29 per share

Miscellaneous

Free Float
12,710,000
Market Cap
$21.37 million
Optionable
Not Optionable
Beta
2.35
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Corey N. Fishman (Age 59)
    President, CEO & Director
    Comp: $1.37M
  • Ms. Judith M. Matthews (Age 54)
    Chief Financial Officer
    Comp: $778.82k
  • Dr. Michael W. Dunne M.D. (Age 64)
    Strategic Advisor & Director
    Comp: $168.15k
  • Dr. Sailaja Puttagunta M.D. (Age 55)
    Chief Medical Officer
    Comp: $755.89k
  • Mr. Tom Loughman Ph.D.
    Senior Vice President of Technical Operations
  • Ms. Louise Barrett
    Senior Vice President of Legal Affairs & Secretary
  • Dr. Steven I. Aronin M.D.
    Senior VP & Head of Clinical Development

ITRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITRM shares.
View ITRM analyst ratings
or view top-rated stocks.

What is Iterum Therapeutics' stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Iterum Therapeutics' stock. Their ITRM share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 261.4% from the stock's current price.
View analysts price targets for ITRM
or view top-rated stocks among Wall Street analysts.

How have ITRM shares performed in 2024?

Iterum Therapeutics' stock was trading at $1.97 at the start of the year. Since then, ITRM shares have decreased by 15.7% and is now trading at $1.66.
View the best growth stocks for 2024 here
.

Are investors shorting Iterum Therapeutics?

Iterum Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,210,000 shares, an increase of 24.1% from the February 29th total of 975,300 shares. Based on an average daily volume of 589,100 shares, the short-interest ratio is presently 2.1 days. Currently, 9.3% of the company's stock are sold short.
View Iterum Therapeutics' Short Interest
.

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our ITRM earnings forecast
.

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) released its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same period in the previous year, the company posted ($5.10) EPS.

When did Iterum Therapeutics' stock split?

Shares of Iterum Therapeutics reverse split before market open on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITRM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners